B-roll satellite distribution advisory - GARDASIL® receives highest recommendation for use in males from National Advisory Committee on Immunization

Most parents agree that vaccinating both boys and girls in school is a good idea

KIRKLAND, QC, Jan. 19, 2012 /CNW Telbec/ - The National Advisory Committee on Immunization (NACI) updated and strengthened its statement related to the use of human papilloma virus (HPV) vaccines in Canada. Among the recommendations, NACI determined that there is good (Grade A, the highest level) evidence to recommend the use of GARDASIL® in males between 9 to 26 years of age. GARDASIL® is the only HPV vaccine indicated and recommended for boys and men.

In addition, a national survey conducted by Ipsos Reid showed that nine in ten parents support the vaccination of boys in school-based programs paid for with public funds.

Watch for the b-roll to be distributed via satellite on Thursday, January 19 between 10:00 am and 11:00 am EDT in English and French and between 12:00 pm and 12:30 pm EDT in English only. Coordinates: Galaxy 17 K13 Slot B, U/L:  14255.5V, D/L: 11955 . 5H, Symbol rate:  6.1113, FEC 3/4.

The news release is available at www.cnw.ca.

Content of footage will include:

  • 12-year-old boy visiting doctor for his first vaccination with GARDASIL®
  • Ipsos Reid representative commenting on survey
  • Footage of genital warts

SOURCE MERCK

For further information:

Montreal
Roch Landriault/Stephanie Lyttle  
NATIONAL Public Relations
514-843-2345/514-843-2365
Toronto
Colin Longhurst
NATIONAL Public Relations
416-848-1393

Profil de l'entreprise

MERCK

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.